ArticleTranslational cancer research2020
Elevated carbohydrate antigen 125 post-operation as a prognostic marker in gastric cancer patients with stage II-III.
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 2 citations in OpenAlex.
- Current and evolving practices of carbohydrate antigens in gastric cancer: a narrative review.Translational cancer research · 2025Review
- Clinical value of CA125, AFP, and CEA for combined diagnosis and assessment of gastric cancer prognosis.Frontiers in oncology · 2025Article
- Prognostic Impact of Perioperative CA125 Status in Gastric Cancer Based on New Cutoff Values.Cureus · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer is one of the high occurrence cancers among gastrointestinal tumor. Further research should be carried out to find more prognostic factors, screening patients with poor prognosis, who need stronger treatment.
methodsThe clinicopathologic characteristic, the levels of tumor markers and survival of 105 patients who underwent gastrectomy with a D2 lymph node dissection in Zhejiang Cancer Hospital were collected and analyzed.
resultsIn the 105 patients, there were 71 males, and the median age was 56 years (range, 21-83 years). In 105 patients, 77 patients were diagnosed with non-cardia cancer, 84.8% patients were diagnosed of poorly differentiated adenocarcinoma, more than half of the patients were diagnosed of T3-4, and 92 patients had lymph node metastasis, while the clinical stage III patients were accounted for 85%. Seventy point five percent patients were Borrmann III type. The median OS of the patients with increased preoperative serum CEA, CA125, CA19-9, AFP and combined were shorter than those patients with normal serum tumor markers, but without statistical significance (P=0.350, P=0.498, P=0.240, P=0.578 and P=0.219). The OS of patients with elevated levels of CEA, CA19-9, and AFP after operation were shorter than patients with decreased ones without statistical significance (P=0.321, P=0.118 and P=0.424). Elevated CA125 after operation was shorter than patients with decreased ones significantly (P<0.005).
conclusionsElevated of CA125 after operation was associated with poor OS in stage II-III GC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.